SCHEMBL2123093

SCHEMBL2123093

CSc1cccc(Nc2c(-c3cccs3)nc3c(C#N)c[nH]n23)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CFTR P13569 4/20 0.47
▸ MAPT P10636 7/20 0.41
▸ TP53 P04637 4/20 0.41
▸ GAA P10253 2/20 0.40
▸ EGFR P00533 2/20 0.38
▸ ERBB2 P04626 1/20 0.38
▸ KDM5A P29375 3/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ PRNP P04156 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ CYP1A2 P05177 2/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ USP2 O75604 1/20 0.36
▸ CASP1 P29466 1/20 0.36
▸ CASP7 P55210 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ HIF1A Q16665 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2123236 0.85 MAPT (0.50) MAPTTP53KDM5A
SCHEMBL2873349 0.85 MAPT (0.49) CFTRMAPTTP53GAAEGFR
SCHEMBL2125620 0.83 KDM5A (0.48) MAPTTP53GAAEGFRERBB2
SCHEMBL2124708 0.83 MAPT (0.42) CFTRMAPTTP53EGFRERBB2
SCHEMBL2125402 0.83 MAPT (0.48) MAPTTP53KDM5A
SCHEMBL2125125 0.82 KDM5A (0.49) CFTRMAPTTP53GAAEGFR
SCHEMBL2132433 0.81 MAPT (0.41) CFTRMAPTTP53GAAEGFR
SCHEMBL2125802 0.81 MAPT (0.44) CFTRMAPTTP53GAAEGFR
SCHEMBL2123871 0.80 MAPT (0.46) MAPTTP53KDM5APOLB
SCHEMBL2126838 0.80 MAPT (0.47) CFTRMAPTTP53EGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443123-B1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS INC (US) 2017-04-05 — — EP disclosed
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 — — US disclosed
EP-2443123-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) Rigel Pharmaceuticals, Inc. (US) 2012-04-25 — — EP disclosed
WO-2010147898-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS, INC. (US) 2010-12-23 — — WO disclosed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) SYK, BTK, LCK CFTR 1623/4885MAPT 4045/4885TP53 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback